Clinical trials: Juvenile Arthritis, active
Polyarticular Course Juvenile Idiopathic Arthritis
Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents
This is a multicenter Phase 3, open-label, single-arm study to evaluate the safety, tolerability, PK, and efficacy of orally administered filgotinib for up to 18 weeks.
- Trial name
- GALAHOPPER (NCT07554495)
- Testing
- Filgotinib
- Where
- 14 sites in Belgium, Czechia and 7 more
- Volunteers
- 65 people
- Sponsor
- Alfasigma S.p.A.
Arthritis, Juvenile, Arthritis, Juvenile Idiopathic
Hypnotherapy for Needle-related Procedural Pain and Anxiety Management in a Pediatric Setting
The proposed study aims to evaluate the effectiveness of hypnotherapy as a non-pharmacological intervention for managing pain and anxiety during needle-related medical procedures in children aged 5 to 17 years.
- Conditions
- Arthritis, Juvenile, Arthritis, Juvenile Idiopathic, Lupus Erythematosus, Systemic, Dermatomyositis, Juvenile
- Trial name
- NCT07349667
- Testing
- Hypnotherapy
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- Aarhus University Hospital
Juvenile Psoriatic Arthritis
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time.
- Trial name
- NCT06100744
- Testing
- Adalimumab, Risankizumab
- Where
- 34 sites in United States, Australia and 7 more
- Volunteers
- 40 people
- Sponsor
- AbbVie
Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
A Registry Study Assessing PRO, Dosing Patterns, and Safety of Vunakizumab in Patients With General Rheumatic Diseases.
Ankylosing spondylitis, radiographically negative axial spondyloarthritis, psoriatic arthritis, polymyalgia rheumatica, Takayasu arteritis, giant cell arteritis, non-ocular Behcet's disease, and enthesitis-related arthritis are…
- Conditions
- Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Nr-axSpA, Polymyalgia Rheumatica (PMR)
- Trial name
- V-MIRACLE (NCT06766552)
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Juvenile Idiopathic Arthritis
Oral Health, Saliva Bacteria, and Disease Activity in Children With JIA: A Cross-Sectional Study.
The goal of this observational study is to learn about the relationship between disease activity and oral health status in children with juvenile idiopathic arthritis (JIA).
- Trial name
- JIA (NCT07799831)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset
A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)
A study to demonstrate efficacy and safety of anakinra in pediatric and adult Japanese patients with Still's disease (Systemic juvenile idiopathic arthritis [SJIA] and Adult-onset Still's disease [AOSD]).
- Trial name
- NCT05814159
- Testing
- Anakinra
- Where
- 8 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Swedish Orphan Biovitrum
Juvenile Idiopathic Arthritis (JIA)
OLE Study With Filgotinib in JIA
This OLE study is designed to evaluate long-term safety, tolerability, and efficacy of filgotinib in patients with polyarticular or systemic juvenile idiopathic arthritis (pJIA-sJIA) who have completed the treatment…
- Trial name
- OLE JIA (NCT07553182)
- Testing
- Filgotinib
- Where
- 4 sites in France, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- Alfasigma S.p.A.
Still Disease
Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease
The primary objective of the study is to evaluate the efficacy and safety of goflikicept (GFC) and olokizumab (OKZ) in patients with Still's disease
- Trial name
- NCT07625384
- Testing
- Goflikicept, Olokizumab
- Where
- 25 sites in Russia
- Volunteers
- 52 people
- Sponsor
- R-Pharm International, LLC
Juvenile Idiopathic Arthritis (JIA)
Structured vs. Exergaming-Based Core Stabilization in Children With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis (JIA) is the most common inflammatory, autoimmune, and chronic rheumatic disease of childhood (1).
- Trial name
- NCT07234747
- Testing
- Structured Core Stabilization Exercise Training, Exergaming-Based Core Stabilization Training
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istanbul University - Cerrahpasa
Juvenile Idiopathic Arthritis
Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis
This open labelled randomized controlled trial will be carried out at the University of Child Health and the Children's Hospital, Lahore consisting of 6 months .
- Trial name
- NCT07386587
- Testing
- Injection, Etanercept, 25 Mg (Code May Be Used for Medicare When Drug Administered Under the Direct Supervision of A Physician, Not for Use When Drug is Self Administered)
- Where
- Pakistan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Child Health Sciences and Children's Hospital, Lahore
Juvenile Idiopathic Arthritis (JIA)
Toward Personalized Medicine to Guide Drug Withdrawal in Children with Juvenile Idiopathic Arthritis in Clinical Remission
Biologic therapies made clinical remission an achievable goal for most juvenile idiopathic arthritis (JIA) patients. Nevertheless, antirheumatic drugs have side effects and are costly.
- Trial name
- Re-JIA (NCT06618937)
- Testing
- Treatment medication withdrawal strategy
- Where
- Italy
- Volunteers
- 166 people
- Sponsor
- Istituto Giannina Gaslini
Juvenile Idiopathic Arthritis Associated Uveitis, Uveitis, Anterior
Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial
The goal of this clinical trial is to learn whether children and young adults with well-controlled juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior uveitis can safely take adalimumab (or biosimilar)…
- Trial name
- ADAPT (NCT07699107)
- Testing
- Adalimumab/Biosimilar
- Where
- 18 sites in United States, Italy and 1 more
- Volunteers
- 160 people
- Sponsor
- Nisha Acharya
Still's Disease, Adult-Onset, Systemic Inflammation
Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
Background: Inflammatory conditions can cause symptoms like fevers, arthritis, and rash. Systemic juvenile idiopathic arthritis (sJIA) is one of these conditions. So is adult-onset Still s disease (AOSD).
- Conditions
- Still's Disease, Adult-Onset, Systemic Inflammation, Arthritis, Autoinflammatory Syndrome
- Trial name
- NCT03510442
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Juvenile Idiopathic Arthritis (JIA)
Angiogenic Biomarkers in Juvenile Idiopathic Arthritis
The aim of the study is to determine whether serum inflammatory angiogenic markers (eg, semaphorins, CCN1) predict severity of juvenile idiopathic arthritis defined by structural progression and/or therapeutic escalation.
- Trial name
- MAJIC (NCT05534347)
- Testing
- Blood sample, Joint puncture
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Systemic Juvenile Idiopathic Arthritis (sJIA), Systemic Juvenile Idiopathic Arthritis
Clinical Features and Treatment of Systemic JIA in Children
This study aims to describe the clinical features, disease patterns, and different treatment modalities used in children with systemic juvenile idiopathic arthritis (sJIA).
- Trial name
- CST-SJIA (NCT07814963)
- Testing
- Tocilizumab (Actemra®)
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Autoimmune Diseases, Lupus Erythematosus, Systemic
Comparative Autoantibody and Immunologic Cell Marker Study
The purpose of this study is to compare immune phenotype, function, and specificity of B lymphocytes from different developmental stages in autoimmune patients to B cells from infectious disease patients and healthy controls.
- Conditions
- Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
- Trial name
- NCT02422875
- Where
- 3 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Emory University
Juvenile Idiopathic Arthritis
Assessment of Composite Inflammatory Ratios in Juvenile Idiopathic Arthritis and Their Association With Disease Activity
Juvenile Idiopathic Arthritis (JIA) is a prevalent pediatric rheumatic disorder characterized by persistent inflammation of one or more joints in children and adolescents.
- Trial name
- NCT07083466
- Testing
- complete blood count, serum albumin
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sohag University
Juvenile Idiopathic Arthritis, Rheumatoid Arthritis
Medical Follow-up of New Cases of Polyarthritis in Children and Young Adults
Population: Juvenile idiopathic arthritis (JIA), rheumatoid arthritis (RA) and seronegative / psoriatic / undifferentiated arthritis (UA), systemic lupus erythematosus (SLE) or diffuse systemic sclerosis dSS).
- Conditions
- Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Psoriatic Arthritis, Systemic Lupus Erythematosus
- Trial name
- NCT07000916
- Where
- Belgium
- Volunteers
- 1,000 people
- Sponsor
- Université Catholique de Louvain
Active Systemic Juvenile Idiopathic Arthritis
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
A multicenter, randomized Phase II/III clinical study to evaluate the efficacy and safety of GenaKumab in the treatment of active systemic juvenile idiopathic arthritis.
- Trial name
- NCT05925452
- Testing
- GenaKumab
- Where
- 10 sites in China
- Volunteers
- 290 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Juvenile Psoriatic Arthritis
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
The purpose of this study is to determine the PK, safety and tolerability of multiple doses of intravenous (i.v.) secukinumab in pediatric participants with JPsA
- Trial name
- NCT06751238
- Testing
- Secukinumab
- Where
- 11 sites in United States
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals